Group 1 - The core viewpoint is that the brain-computer interface (BCI) industry is experiencing significant policy support and technological breakthroughs, leading to a promising commercialization outlook [2] - The National Medical Products Administration has prioritized the approval of implantable BCI medical devices, with expected registration certificates to be issued gradually in the first quarter of 2026 [1][2] - The National Healthcare Security Administration is guiding local authorities to establish pricing standards for invasive and non-invasive BCI procedures, facilitating clinical application and payment pathways [1][2] Group 2 - The China Securities Medicine and Medical Device Innovation Index (931484) shows mixed performance among its constituent stocks, with New Hope leading at a 1.99% increase, while Gan Li Pharmaceutical is the biggest loser [1] - The top ten weighted stocks in the China Securities Medicine and Medical Device Innovation Index account for 63.75% of the index, including companies like WuXi AppTec and Mindray [3] - The Medical Innovation ETF closely tracks the China Securities Medicine and Medical Device Innovation Index, reflecting the overall performance of profitable and growth-oriented companies in the pharmaceutical and medical device sectors [2]

Core Points - The National Medical Products Administration (NMPA) has released the "Priority Approval Directory for High-end Medical Devices (2025 Edition)" which includes eight types of products such as boron neutron capture therapy systems and high-field magnetic resonance imaging equipment [1][2] - The directory aims to implement the State Council's directive on deepening the reform of drug and medical device regulation to promote high-quality development in the pharmaceutical industry [1] - The NMPA will prioritize the approval process for the listed medical devices according to specific regulations, ensuring a streamlined review process for these innovative products [1] Summary by Categories Product Categories - The directory includes eight high-end medical devices: 1. Boron neutron capture therapy systems 2. High-field magnetic resonance imaging equipment 3. Medical electron accelerators 4. Implantable brain-machine interface medical devices 5. Endoscopic surgical control systems 6. Transcatheter tricuspid valve replacement or repair systems 7. Implantable glaucoma drainage devices for minimally invasive glaucoma surgery (MIGS) 8. Membrane oxygenators for ECMO [1] Regulatory Framework - The NMPA has established the directory in accordance with the "Regulations on the Registration and Filing of Medical Devices" and the announcement on optimizing lifecycle supervision to support the innovative development of high-end medical devices [1] - The approval process will follow Article 73, Item 3 of the Medical Device Registration and Filing Management Measures, allowing for expedited review of applications for the listed devices [1] Implementation and Future Adjustments - The directory will take effect immediately upon publication, with the NMPA indicating that it may adjust the list as necessary in the future [2]

Market Overview - The A-share market opened strongly in 2026, with the Shanghai Composite Index surpassing 4000 points, closing up 1.38% [1] - The total trading volume reached 2.57 trillion yuan, an increase of 501.5 billion yuan compared to the previous trading day [1] - The market saw over 4100 stocks rise, indicating broad-based gains across sectors [1] Historical Context - The Shanghai Composite Index achieved a record 12 consecutive daily gains from December 17, 2025, to January 5, 2026, marking the longest streak since 1993 [3] - Previous records included an 11-day streak in 2006 and 2017-2018, while extreme cases like the 99-day streak in 1991-1992 are less relevant due to the smaller market size at that time [3] Sector Performance - The brain-computer interface sector led the market, with over thirty stocks hitting the daily limit up, including Sanbo Brain Science and Meihao Medical [6] - The insurance sector also saw significant gains, with Xinhua Insurance and China Pacific Insurance reaching new historical highs [6] - The commercial aerospace sector remained active, with stocks like Reco Defense and China Satellite Communications showing strong performance [6] - The semiconductor industry showed strength, with stocks such as Yaxin Integration and Shenghui Integration hitting the daily limit up [6] Investment Insights - Analysts suggest focusing on the pressure level around 4034 points for potential breakthroughs, indicating a continuation of the short-term bullish trend [5] - The brain-computer interface sector is expected to benefit from policy support, with the inclusion of high-end medical devices in priority approval lists [8] - The semiconductor market is projected to benefit from ongoing supply shortages and strong demand, with companies like Micron expected to perform well [16] Future Outlook - Goldman Sachs released a report recommending an overweight position in Chinese stocks for 2026, highlighting structural growth in exports and investment rebound supported by policy [18] - The report anticipates a 15% to 20% annual increase in the Chinese stock market for 2026 and 2027, driven by a focus on modernizing the industrial system and enhancing technological self-reliance [18]

Group 1 - The medical device sector experienced a strong start in 2026, with multiple stocks hitting the daily limit up, including Mindray Medical, United Imaging, and South Micro Medical, among others [1] - The Medical Device Index ETF (159898) saw a significant increase of over 5%, with a net subscription of 27 million units and a net inflow of over 15 million yuan [1][2] - Recent government initiatives, such as the National Medical Products Administration's (NMPA) establishment of a priority approval list for high-end medical devices, aim to accelerate the market entry of innovative products [3] Group 2 - The medical device sector has gained attention in specific areas like brain-computer interfaces, indicating potential for continued performance [3] - The NMPA's new regulations on export sales certificates for medical devices will facilitate better pricing strategies for companies in the global market [3] - Century Securities suggests that domestic medical device manufacturers have gained significant market share post-consolidated procurement, benefiting from scale effects and export policies [4] Group 3 - The Medical Device Index ETF (159898) tracks the CSI All-Index Medical Devices, with major holdings in leading companies like Mindray Medical and United Imaging, reflecting a strong representation of the A-share medical device sector [4]

Core Viewpoint - The medical device sector is experiencing significant growth, with notable stock increases for companies like Lepu Medical, Mindray, and United Imaging, driven by favorable regulatory developments and market sentiment [1][2]. Group 1: Stock Performance - Lepu Medical's stock surged by 20%, while Mindray and United Imaging saw increases of over 4% [1]. - Medical device-related ETFs rose by more than 5%, indicating strong investor interest in the sector [1]. Group 2: Regulatory Developments - The National Medical Products Administration has developed a "Priority Approval List for High-end Medical Devices (2025 Edition)," which includes advanced technologies such as medical electronic accelerators and implantable brain-machine interface devices [2]. - The inclusion of these high-end products in the priority approval category highlights the government's support for technological advancements in the medical device industry [3]. Group 3: Market Potential - The brain-machine interface sector is characterized by diverse application scenarios and rich research and development pathways, suggesting a broad potential market space [3]. - With supportive policies for product registration and medical insurance project approvals, the commercialization process for these technologies is expected to accelerate [3].

Group 1 - A-shares opened higher today, with significant gains in innovative drug and brain-computer interface stocks, including Zhaoyan New Drug and BeiGene, which rose over 10% [1] - The innovative drug ETF Tianhong (517380) tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index surged over 4.8%, outperforming the Hong Kong Stock Connect Innovative Drug Index [1] - The biopharmaceutical ETF (159859) tracking the Guozhen Biopharmaceutical Index increased by over 3%, with a total scale exceeding 3.3 billion yuan and a net inflow of over 600 million yuan since September last year [1] Group 2 - The National Medical Products Administration has organized the formulation of the "Priority Approval High-end Medical Device Catalog (2025 Edition)," including medical electronic accelerators and implantable brain-computer interface medical devices [1] - Elon Musk announced that his brain-computer interface company, Neuralink, will begin large-scale production of brain-computer interface devices in 2026, transitioning to a more streamlined and nearly fully automated surgical process [1] - Analysts indicate that including implantable brain-computer interface medical devices in the priority approval category highlights policy support for related technological developments, with a broad potential market space and accelerated commercialization processes expected [1] Group 3 - McKinsey estimates that the global market size for brain-computer interface medical applications could reach $40 billion by 2030 and $145 billion by 2040, indicating significant application potential in the medical field [2] - Investors interested in the innovative drug sector can consider the innovative drug ETF Tianhong (517380) for easy access, while off-market investors may focus on linked funds [2] - The emphasis is on CXO and innovative drug mainline trends, with a recommendation to focus on the biopharmaceutical ETF (159859) that targets 30 industry leaders for higher sharpness and elasticity [2]

Core Viewpoint - The National Medical Products Administration (NMPA) of China has released the "Priority Approval Catalog for High-end Medical Devices (2025 Edition)", which includes eight advanced medical devices for expedited approval, aiming to accelerate the market entry of innovative high-end medical equipment [1]. Group 1: Priority Approval Catalog - The catalog includes advanced medical devices such as the boron neutron capture therapy system, ultra-high field magnetic resonance imaging equipment, medical electron accelerators, and implantable brain-machine interface devices [1][2]. - The NMPA will implement priority approval for the medical devices listed in the catalog according to Article 73, Item 3 of the "Regulations on the Registration and Filing of Medical Devices" [1][5]. Group 2: Device Specifications - The boron neutron capture therapy system is designed to treat malignant tumors that are recurrent or for which there are no other conventional treatment options, utilizing a reaction between neutrons and boron to produce secondary particles that kill cancer cells [2]. - The ultra-high field magnetic resonance imaging equipment has a magnetic field strength greater than 5 Tesla [2]. - The medical electron accelerator integrates magnetic resonance imaging guidance and is used for various therapeutic applications [2]. - The implantable brain-machine interface device captures neural signals from the central nervous system through implanted electrodes, enabling interaction with external control devices for compensating motor and sensory dysfunctions [2]. - The endoscopic surgical control system employs robotic technology for operating surgical instruments through natural orifices [2]. - The transcatheter tricuspid valve repair system is suitable for high-risk patients with severe tricuspid regurgitation who are deemed unsuitable for surgical intervention [2]. - The minimally invasive glaucoma surgery (MIGS) implant establishes a drainage pathway for aqueous humor in the eye [2].

Market Overview - The A-share market experienced mixed performance with the Shanghai Composite Index recording a "9 consecutive days of gains" as of December 29, 2023, marking a slight increase of 0.04% [1] - The Shenzhen Component Index and the ChiNext Index fell by 0.49% and 0.66% respectively, while the North Star 50 Index decreased by 0.45% [1] - Total trading volume in the Shanghai and Shenzhen markets was 21,577 billion yuan, a decrease of 234 billion yuan from the previous day [1] Multi-Financial Sector - The multi-financial sector showed active performance, with stocks like Lakala leading the gains, and companies such as Cuiwei Co., Luxin Venture Capital, and Yuexiu Capital reaching around 10% limit up [3] - On December 26, the Shanghai Stock Exchange announced new guidelines to support high-quality commercial rocket enterprises under the Sci-Tech Innovation Board, which is expected to accelerate the development of the commercial aerospace industry [3] - The rapid growth of the commercial aerospace sector is projected to create significant market opportunities for carbon fiber composite materials, which can account for 70%-90% of the structural weight in spacecraft [3] Carbon Fiber Industry - Shanxi Securities noted that leading companies in the carbon fiber industry are announcing price increases, indicating a recovery in industry conditions [4] - The market for carbon fiber is showing clear differentiation, with general products facing strong competition, while high-end applications in aerospace, hydrogen storage, and wind power require consistent performance and reliable supply [4] - According to Baichuan Yingfu, China's actual consumption of carbon fiber is expected to reach 96,446 tons in 2025, a year-on-year increase of 71.89%, primarily driven by the wind power and aerospace sectors [4] Brain-Computer Interface Sector - The brain-computer interface sector saw significant gains, with Haige Communication reaching around 10% limit up, followed by companies like Meihao Medical and Mcland [5] - On December 26, the National Medical Products Administration released a list of high-end medical devices for priority approval, which includes implantable brain-computer interface devices [5] - The global brain-computer interface market is currently valued at several billion dollars and is expected to exceed 10 billion dollars by 2030, with the medical application market projected to reach 40 billion dollars by 2030 and 145 billion dollars by 2040 according to McKinsey [5][6]

Investment Rating - The industry investment rating is "Positive" and is maintained [7] Core Insights - The computer sector has shown a continuous rebound, with an overall increase of 2.13%, ranking 14th among primary industries in the Yangtze River region, and accounting for 5.77% of the total market turnover [2][4][13] - The report highlights significant advancements in the brain-computer interface (BCI) industry, particularly with the upcoming Shenzhen Brain Expo, which is expected to accelerate the commercialization of BCI technologies [6][49] - The report suggests focusing on three main lines of investment: 1) domestic mapping of invasive BCI technologies from advanced overseas industries; 2) product deployment of non-invasive BCIs in consumer scenarios; 3) downstream applications related to BCIs [6][62] Summary by Sections Market Performance - The computer sector's performance last week was characterized by a strong market rebound, with the Shanghai Composite Index returning to 3900 points, closing at 3963.68 points, reflecting an overall increase of 1.88% [4][13] - The computer sector's turnover accounted for 5.77% of the total market, with notable activity in commercial aerospace and space computing-related stocks [2][4] Key Developments - The report emphasizes the recent achievements in quantum error correction by the University of Science and Technology of China, marking a significant milestone for future large-scale fault-tolerant quantum computing [10][22] - The successful launch of the Long March 12 rocket and the support from the Shanghai Stock Exchange for commercial rocket enterprises are highlighted as pivotal developments in the commercial aerospace sector [30][40] Investment Opportunities - The report identifies the BCI industry as a key area for investment, particularly in light of supportive policies and the potential for rapid commercialization [6][62] - The upcoming Shenzhen Brain Expo is expected to showcase advancements and foster investment opportunities in the BCI sector [49][62] - The report also notes the acceleration of IPO processes for commercial aerospace companies, which could enhance capital flow into the industry [40][48]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth driven by favorable policies, technological advancements, and increased investment interest, as evidenced by the recent surge in stock prices of related companies in both Hong Kong and A-share markets [2][6][7]. Policy Developments - The National Medical Products Administration has included implantable brain-computer interface medical devices in the "Priority Approval List for High-end Medical Devices (2025 Edition)" [2]. - A joint initiative by seven ministries, including the Ministry of Industry and Information Technology, has set phased goals for the BCI industry by 2027 and 2030 [3]. - The "14th Five-Year Plan" emphasizes the BCI sector as a key area for fostering new economic growth [4]. - The National Healthcare Security Administration has introduced new pricing guidelines for invasive BCI procedures, facilitating reimbursement pathways [4]. Technological Advancements - Recent breakthroughs in BCI technology include the first domestically developed fully implanted, wireless BCI product by Brain Tiger Technology, which successfully completed its first clinical trial [5]. - The National Medical Products Administration has approved the world's first invasive BCI product for treating addiction-related mental disorders [5]. - Ongoing clinical trials and collaborations among research institutions and medical units are yielding significant progress in the field [5]. Market Insights - The BCI industry is entering a rapid commercialization phase, supported by policy backing, technological breakthroughs, and increased capital influx [5][6]. - The market for BCI is projected to be a nearly $10 billion opportunity globally, with domestic companies making strides in flexible electrodes and real-time Chinese language decoding [7]. - Investment interest in the BCI sector is rising, particularly in rehabilitation applications and non-invasive BCI technologies, as companies strategically position themselves for future growth [6][7].